Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors

類似資料

• A multicentre, open‐label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors
  著者:: Shima, Midori, 等
  出版事項: (2019)
• A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A
  著者:: Yoneyama, Koichiro, 等
  出版事項: (2017)
• Long‐term safety and efficacy of emicizumab for up to 5.8 years and patients’ perceptions of symptoms and daily life: A phase 1/2 study in patients with severe haemophilia A
  著者:: Shima, Midori, 等
  出版事項: (2020)
• Spotlight on emicizumab in the management of hemophilia A: patient selection and special considerations
  著者:: Yada, Koji, 等
  出版事項: (2019)
• Spotlight on emicizumab in the management of hemophilia A: patient selection and special considerations
  著者:: Yada K, 等
  出版事項: (2019-07-01)